XML 23 R11.htm IDEA: XBRL DOCUMENT v3.6.0.2
Deferred Grant Income
 12 Months Ended
Sep. 30, 2016
Deferred Revenue Disclosure [Abstract]  
Deferred Grant Income
  Note 4 Deferred Grant Income

 

During the year ended September 30, 2015, the Company was awarded grant funding in the amount of $286,455, of which the Company received $143,222 during the year ended September 20, 2016 (2015 - $71,614) and the remainder will be received in equal semi-annual instalments over the remainder of the commitment through January 2017. The grant was received in exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential treatment for Parkinsons disease.

 

The grant income was deferred and is being amortized as an increase to other income over a two-year period as the related research and development expenditures are incurred. During the year ended September 30, 2016, the Company recognized $141,195 (2015: $0, 2014: $0) of this grant on its statement of operations within grant income.

 

During the year ended September 30, 2016, the Company recognized other grant income of $571,093 in respect of a research and development incentive program offered by the Australian government. This grant income is included on its statement of operations within grant income.